Navigation Links
Nektar Therapeutics Announces Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million
Date:2/29/2012

SAN FRANCISCO, Feb. 29, 2012 /PRNewswire/ --  Nektar Therapeutics (Nasdaq: NKTR) today announced that it agreed to sell to Royalty Pharma its royalties on future sales of CIMZIA®, under Nektar's agreement with UCB Pharma, and MIRCERA®, under Nektar's agreement with Roche. In consideration for the sale, Royalty Pharma will pay Nektar an aggregate cash payment of $124.0 million.

Nektar intends to use the net proceeds of the transaction towards the repayment of its $215.0 million of convertible debt.  For the twelve month period ended December 31, 2011, Nektar recognized $8.3 million in aggregate royalties from net sales of CIMZIA® and MIRCERA®.

"This transaction demonstrates our ability to unlock unrecognized value in Nektar's legacy collaborations and access significant capital in a non-dilutive transaction," said Howard W. Robin, President and Chief Executive Officer of Nektar.  "The proceeds from this sale will strengthen our cash position considerably and we are pleased to have Royalty Pharma as our partner in this transaction."

Pablo Legorreta, Chief Executive Officer of Royalty Pharma, stated, "We are pleased to have had the opportunity to work with Nektar in this important transaction. Royalty Pharma's goal is to be the preferred financial partner to leading biopharmaceutical companies seeking to access capital from their passive royalty assets. The CIMZIA® and MIRCERA® royalties are very high quality assets that will be an excellent addition to our diversified portfolio of leading biopharmaceutical royalties."

Pursuant to the agreement entered into between Nektar and RPI Finance Trust, an affiliate of Royalty Pharma, RPI Finance Trust will receive all royalties on worldwide net sales of CIMZIA® and MIRCERA® from and after January 1, 2012.  If certain worldwide net sales thresholds for MIRCE
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicines 28th Annual Meeting
2. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2011 on Wednesday, February 29, 2012, After Close of U.S.-Based Financial Markets
3. Positive Data for Nektars New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011
4. Nektar Therapeutics Reports Third Quarter 2011 Financial Results
5. Nektar to Announce Financial Results for the Third Quarter of 2011 on Wednesday, November 2, 2011, After Close of U.S.-Based Financial Markets
6. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the UBS 2011 Global Life Sciences Conference in New York City
7. Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
8. Nektar Therapeutics Reports Second Quarter 2011 Financial Results
9. Nektar to Announce Financial Results for the Second Quarter of 2011 on Thursday, August 4, 2011, After Close of U.S.-Based Financial Markets
10. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
11. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... Over-the-counter healthcare costs can be a ... new survey of store brand over-the-counter products aimed ... to diabetes, can offer significant savings for those ... Private Label Manufacturers Association, assembled a market basket ... essential for treatment of pre-diabetes and diabetes. These ...
(Date:3/26/2015)... 2015  Desert Valley Medical Center, named a Top ... is the first U.S. hospital to deploy the wireless ... help clinicians prevent hospital acquired pressure ulcers. ... , is a community hospital serving some higher risk ... Patient Monitor in the hospital,s emergency department enables the ...
(Date:3/26/2015)... Californie, 26 mars 2015 Finesse Solutions ... conçu pour les innovateurs, visionnaires et cadres de ... conférence d,une durée de deux jours proposée exclusivement ... dans le centre ville de San ... 2015. Il s,agira d,un forum destiné aux leaders ...
Breaking Medicine Technology:Consumers can keep over-the-counter medicine affordable by using store brands 2Desert Valley Medical Center First to Use Leaf Healthcare Patient Wearable Technology in its ED as Part of Hospital-wide Deployment 2Desert Valley Medical Center First to Use Leaf Healthcare Patient Wearable Technology in its ED as Part of Hospital-wide Deployment 3Finesse Solutions annonce l'événement Cellworld 2015 2
... Its USD520.6 million Sale to Sanofi-... -- PARIS, Nov. 1, 2010 /PRNewswire-Asia/ -- ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... NeoStem, Inc. (NYSE Amex: NBS ) ... operations in the U.S. and China, today announced that ... (China), Inc., the Company,s wholly-owned subsidiary, will present "Building ... Therapy Industry Summit 2010 hosted by Life Technologies Corporation ...
Cached Medicine Technology:E. J. McKay Advises BMP Sunstone on Its USD520.6 million Sale to Sanofi- aventis 2E. J. McKay Advises BMP Sunstone on Its USD520.6 million Sale to Sanofi- aventis 3E. J. McKay Advises BMP Sunstone on Its USD520.6 million Sale to Sanofi- aventis 4E. J. McKay Advises BMP Sunstone on Its USD520.6 million Sale to Sanofi- aventis 5E. J. McKay Advises BMP Sunstone on Its USD520.6 million Sale to Sanofi- aventis 6E. J. McKay Advises BMP Sunstone on Its USD520.6 million Sale to Sanofi- aventis 7E. J. McKay Advises BMP Sunstone on Its USD520.6 million Sale to Sanofi- aventis 8NeoStem to Present at Cell Therapy Industry Summit to be held on November 3-5, 2010 in Carlsbad, California 2NeoStem to Present at Cell Therapy Industry Summit to be held on November 3-5, 2010 in Carlsbad, California 3
(Date:3/26/2015)... “The SWEET Act is an important step ... available and help parents who are working to reduce sugar ... approach to support public health, and we will continue to ... health of all families,” said Dr. Jane Delgado President and ... introduction of the Sugar-Sweetened Beverage Tax (SWEET) Act by Congresswoman ...
(Date:3/26/2015)... Dr. Alex Rabinovich and his San Francisco ... for Bay Area patients considering dental implants or teeth ... been a top-rated center, serving primarily San Franciscans; however, ... strong demand by others throughout Northern California. , “We ... implant facility in San Francisco,”explained Dr. Alex Rabinovich, owner ...
(Date:3/26/2015)... Springs, FL (PRWEB) March 26, 2015 ... of the nation’s leading innovative specialty pharmacies, announces ... created position of Vice President of Pharmaceutical Relations. ... fostering beneficial connections with our pharmaceuticals partners and ... relationships in support of BioPlus’ expansion. , ...
(Date:3/26/2015)... UK (PRWEB) March 26, 2015 In the ... billion as of 2013 and is set to decrease through ... by 2020; the growth is expected up to 2017 at ... is expected to be owing to the surging penetration of ... HCT, Twynsta, Micardis Plus, Valturna, Benicar HCT, and Tekamlo), a ...
(Date:3/26/2015)... Sunrise, FL (PRWEB) March 26, 2015 ... unveiled its brand-new, state-of-the-art company website: http://www.metabolicnutrition.com ... of the revamped website creates a user-friendly experience ... supplement company. , The new, enhanced Metabolic ... Comprehensive information about the company’s diverse line of ...
Breaking Medicine News(10 mins):Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act in 114th Congress 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 3Health News:BioPlus Specialty Pharmacy Expands Executive Team with New Position, Naming Sharon Ferrer as Vice President of Pharmaceutical Relations 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3Health News:Metabolic Nutrition Launches Sleek New Website with New Features and Enhanced Consumer Information 2
... use of alternative or complementary therapies have increased over ... using // at least one form of alternative medicine. ... yoga, hypnosis, acupuncture, chiropractic care, and high-dose vitamins. ... own survey taken in 1997 to the National Health ...
... disorder, where white blood cells attack fatty tissue surrounding nerve ... is twice as common in women as in men . ... with multiple sclerosis. Since MS causes muscle weakness and fatigue, ... of life, researchers designed an exercise program to develop ...
... days of physical inactivity, the body's efficient use of insulin ... ,Researchers conducted a study in rats and found insulin sensitivity ... stopped running for two days after a period of running ... muscle in response to insulin was found to have decreased ...
... Duchenne muscular dystrophy (DMD) with the oral steroid prednisone is ... effects of the drug . Most patients with this form ... 20s from respiratory failure or heart problems. Despite the beneficial ... side effects, which can range from weight gain to behavioral ...
... people who carry a gene that produces a higher ... increased risk for stroke.// ,Researchers reviewed medical literature ... that previous study results were observational in nature. A ... factors by looking at data on the link between ...
... coronary heart disease who follow a heart-healthy diet and ... // medications that raise HDL (high-density lipoproteins or "good" ... studied 143 patients younger than 76 with low HDL ... study followed a heart-healthy diet and lost weight. However, ...
Cached Medicine News:
... Sun Med TruFlow™ Oxygen flowmeter with ... lifetime warranty covering calibration and manufacturing defects. ... to meet most needs. Also available with ... auxiliary power take-off and double unit configurations. ...
... TruFlow™ Oxygen flowmeter with a Lexan®inner calibrated ... calibration and manufacturing defects. A wide range ... needs. Also available with all popular inlet ... and double unit configurations. Our extra large ...
... Oxygen flowmeter with a Lexan®inner calibrated flow ... and manufacturing defects. A wide range of ... Also available with all popular inlet connections, ... double unit configurations. Our extra large knob ...
... Sun Med TruFlow™ Oxygen flowmeter with ... lifetime warranty covering calibration and manufacturing defects. ... to meet most needs. Also available with ... auxiliary power take-off and double unit configurations. ...
Medicine Products: